Inhibition of histone deacetylase as a treatment for cardiac hypertrophy

Abstract

The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.

1 - 10 . (canceled)  
     
     
         11 . A method of preventing heart failure comprising: 
 (a) identifying a patient at risk of developing heart failure; and    (b) administering to said patient a histone deacetylase inhibitor.    
     
     
         12 . The method of  claim 11 , wherein said histone deacetylase inhibitor is selected from the group consisting of trichostatin A, trapoxin B, MS 275-27, m-carboxycinnamic acid bis-hydroxamide, depudecin, oxamflatin, apicidin, suberoylanilide hydroxamic acid, Scriptaid, pyroxamide, 2-amino-8-oxo-9,10-epoxy-decanoyl, 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamide and FR901228.  
     
     
         13 . The method of  claim 11 , wherein administering comprises intravenous administration of said histone deacetylase inhibitor.  
     
     
         14 . The method of  claim 11 , wherein administering comprises oral, transdermal, sustained release, suppository, or sublingual administration.  
     
     
         15 . The method of  claim 11 , wherein the patient at risk may exhibit one or more of long standing uncontrolled hypertension, uncorrected valvular disease, chronic angina and/or recent myocardial infarction.  
     
     
         16 - 50 . (canceled)